This bill amends the Chemical and Biological Weapons Control and Warfare Elimination Act of 1991 to create a new pathway for imposing mandatory sanctions on a foreign country when a covered individual—an official, employee, or agent of a foreign governmental entity—commits an act tied to a chemical or biological program that injures another country. It inserts an individual-focused determination process that, if made, compels a sequence of sanctions against the country most closely associated with that entity.
The statutory package sets out short, intermediate, and final sanction stages with precise timelines: the President must decide within 60 days whether an individual committed a covered act, impose initial sanctions within 30 days, report to Congress at 120 and 210 days, and apply broader trade and financial prohibitions if the foreign entity does not remedy the conduct. The bill also defines specific fentanyl-related chemicals and expands the definition of foreign governmental entity, tying export controls, foreign assistance, and financial prohibitions to compliance with chemical and biological treaty obligations.
At a Glance
What It Does
The bill adds a new trigger to the CBW Act allowing the President to determine whether a foreign official committed a 'covered act' involving a chemical or biological program and then impose mandatory, staged sanctions on the country most closely associated with that entity. Sanctions range from suspending scientific cooperation and restricting Commerce Control List items to prohibiting U.S. transactions and cutting foreign assistance.
Who It Affects
Primary targets are foreign governments and entities involved in chemical or biological programs — explicitly including production of certain fentanyl substances and precursors — plus researchers and institutions participating in bilateral scientific programs, exporters of dual‑use goods, and financial institutions handling transactions tied to the targeted country. U.S. agencies that administer export controls and foreign assistance will have new enforcement and reporting duties.
Why It Matters
This statute converts individual-level wrongdoing into mandatory country-level sanctions, narrows timelines for presidential action, and explicitly links fentanyl precursor production to the CBW framework. For compliance teams, it creates a fast‑moving enforcement ladder that can cascade from export controls to broad financial prohibitions, altering risk assessments for international partnerships and exports.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill creates a new enforcement track inside the Chemical and Biological Weapons Control and Warfare Elimination Act that starts with an allegation: when credible information suggests a foreign official has committed an act tied to a chemical or biological program that injures a third country, the President must decide within 60 days whether the act occurred. The decision process requires the executive to weigh physical and circumstantial evidence, whether the program has civilian or military purpose, and whether the foreign entity cooperated with international organizations and treaty obligations.
If the President determines a covered act occurred, the statute forces an immediate set of initial sanctions against the foreign country most closely associated with the responsible entity. Within 30 days the United States must suspend scientific cooperation, block exports of Commerce Control List Category 1 and 2 items, and bar U.S. procurement from that country’s chemical/biological sectors.
Those are mandatory and automatic once the individual-level finding is made.The law then defines a 120-day checkpoint: the executive reports to the relevant congressional committees whether the foreign entity addressed the act, provided substantive information, and adopted preventive measures, and whether the country is meeting its obligations under the Biological and Chemical Weapons Conventions. If the country has not taken those steps, the President must impose at least two intermediate sanctions — options include terminating foreign assistance (with humanitarian exceptions) and imposing export controls under the Export Control Reform Act or arms export rules.A final 210-day determination can escalate to an even broader prohibition: if corrective steps remain inadequate, the President must bar transactions in foreign commerce and financial transfers involving a financial interest of the country and subject to U.S. jurisdiction.
The statute provides a one‑year review and conditional termination route (certification to Congress), allows temporary national‑security waivers up to 180 days, and sunsets the waiver authority after five years. The bill also enumerates covered chemicals (benzylfentanyl, 4‑anilinopiperidine, norfentanyl precursors) and broadens the definition of foreign governmental entity to capture entities that receive significant government support or act as agents.
The Five Things You Need to Know
The President must determine within 60 days whether a foreign official committed a 'covered act' tied to a chemical or biological program and impose sanctions under section 310 if so.
Within 30 days of that determination the statute requires three initial sanctions against the associated country: suspension of scientific cooperation, prohibition on export/reexport of Commerce Control List Category 1 and 2 items, and a ban on U.S. procurement from that country’s chemical/biological sectors.
At 120 days the President must report to Congress on remediation and treaty compliance; if the country hasn’t adequately addressed the act, the President must impose at least two intermediate sanctions (e.g.
terminate most foreign assistance, broaden export controls).
If remediation remains insufficient at 210 days the President must prohibit transactions in foreign commerce or financial transfers involving the country’s financial interests that are subject to U.S. jurisdiction.
The statute defines 'chemical or biological program' to include fentanyl-related substances (benzylfentanyl, 4-anilinopiperidine, norfentanyl precursors) and expands 'foreign governmental entity' to include entities that receive significant material support or act as agents, widening the pool of targets.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Expands Act purposes to include acts causing injury via chemical/biological programs
This amendment broadens the stated purposes of the CBW Act to cover not just state use or programs that violate treaty obligations, but also acts by government officials tied to chemical or biological programs that cause injury to other countries. Practically, it frames cross‑border harms (including those connected to fentanyl precursor production) as a statutory rationale for sanctions and clears the way for country-level responses tied to individual conduct.
Creates an individual-based determination process and reporting deadlines
Section 306 is rewritten to require the President to make a finding about an identified individual within 60 days of credible information and to document that finding to Congress. The law sets out specific factors the President must consider — evidence, civilian vs. military purpose, concealment or cooperation with international organizations, and treaty compliance — and it differentiates between determinations about weapons programs and determinations about programs that caused injury, with separate reporting content requirements for each.
Initial sanctions — automatic suspension and export/procurement prohibitions
Once an individual-level determination under section 306(a)(1)(B) is made, the President has 30 days to impose a fixed set of initial sanctions against the country most closely associated with the entity. These are non-discretionary under the statutory text: suspend scientific cooperative programs, ban exports/reexports of Commerce Control List Category 1 and 2 items to that country, and prohibit procurement from firms in the country's chemical/biological sectors. These measures hit academic, governmental, and commercial exchanges quickly.
Intermediate and final sanctions — escalating export, aid, and financial measures
At 120 days the President reports on remediation and must choose at least two intermediate sanctions if the country hasn’t sufficiently acted. The options tie into existing regimes (Foreign Assistance Act, Export Control Reform Act, Arms Export Control Act) and allow broad export and licensing prohibitions. At 210 days the statute empowers the President to block foreign‑commerce transactions and financial transfers that are subject to U.S. jurisdiction and involve the country’s financial interest — a structural escalation that can throttle trade and global payments involving the target.
Termination, waivers, and time limits
Sanctions can be terminated if, within a year, the President certifies to Congress that the country or entity addressed the act, provided restitution, cooperated with international bodies, and is meeting treaty obligations. The President can waive sanctions for up to 180 days on national security grounds, but that waiver authority sunsets after five years — a built-in limitation on executive flexibility intended by the drafters.
Substantive definitions that extend coverage to fentanyl precursors and broad entity definitions
This new definitions section places certain fentanyl-related chemicals explicitly within the CBW frame, names the Commerce Control List by reference, and broadens 'foreign governmental entity' to capture agencies, instrumentalities, entities acting as agents, and even commercially active organizations that receive significant material support. That expansion makes it easier to reach private or quasi‑private actors tied to state programs.
Technical fix to preserve existing cross-references
A single-line conforming amendment updates a statutory cross-reference to reflect the new subdivisioning of section 306. It prevents confusion in statutory citations and ensures older references point to the correct subparagraph after the insertion of the new individual‑based determination text.
This bill is one of many.
Codify tracks hundreds of bills on Foreign Affairs across all five countries.
Explore Foreign Affairs in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Countries and populations harmed by cross-border chemical/biological acts: The statute provides a formal U.S. mechanism to hold state‑linked actors accountable and to press for remediation and restitution on behalf of injured third countries.
- U.S. national security and law enforcement agencies: The bill supplies clear statutory authorities, timeframes, and reporting requirements that streamline the executive branch’s ability to escalate responses and synchronize export control and financial tools.
- Congressional oversight committees: Committees on Foreign Affairs and Foreign Relations gain structured reporting triggers (60/120/210-day reports and certifications) that enhance legislative visibility and leverage over executive implementation.
- Producers or distributors of lawful pharmaceuticals in compliant countries: If sanctions disrupt illicit precursor networks abroad, compliant firms could face reduced illicit competition and clearer supply‑chain standards over time.
Who Bears the Cost
- Targeted foreign governments and state‑linked entities: They will face immediate academic and scientific decoupling, export control restrictions, procurement bans, and potentially sweeping financial prohibitions that damage trade and revenue.
- Academic, research, and scientific institutions engaged in bilateral programs: Mandatory suspension of scientific cooperation can halt joint research projects, clinical trials, and public‑health collaboration, with downstream effects on international science.
- Exporters of dual‑use goods and defense/chemical firms: Companies that trade Commerce Control List Category 1 and 2 items will face tightened licensing and potential market losses where country partners are sanctioned.
- Financial institutions and compliance teams: Banks and payment processors may need to implement new screening and blocking procedures to prevent transactions 'involving a financial interest of the country,' increasing compliance costs and legal risk exposure for cross-border business.
Key Issues
The Core Tension
The bill’s central dilemma is between aggressive deterrence and attribution on one hand—using swift, mandatory country-level sanctions to punish state-linked weaponization or illicit fentanyl production—and the risk on the other hand that blunt, automatic penalties will harm non‑culpable researchers, civilians, and international cooperation, particularly where evidence is ambiguous or where private actors with governmental ties are involved.
The bill uses low‑to‑moderate evidentiary language—'credible information' and factors the President 'shall consider'—but does not prescribe a clear legal standard for attribution or the threshold for country-level culpability. That creates practical ambiguity for adjudicating when mandatory sanctions must follow an individual finding.
The transformation from an individual act into required country-level measures also raises proportionality and collateral‑impact questions: mandatory suspension of scientific collaboration and export prohibitions can disrupt legitimate public‑health, climate, and basic‑research work before there is any cure or remediation.
Operationally, the statute stitches together multiple statutory regimes (Foreign Assistance Act, Export Control Reform Act, Arms Export Control Act, Commerce Control List, financial jurisdiction rules) and thereby increases the need for interagency coordination. Implementation will require close alignment among State, Commerce, Treasury, and other agencies to interpret definitions (especially 'foreign governmental entity' and the listed fentanyl precursors), to sequence actions without legal conflict, and to manage exemptions (humanitarian exceptions for assistance).
Finally, the provision authorizing waivers for national security up to 180 days is a safety valve but its five‑year sunset creates a limited escape hatch that could complicate diplomacy if the executive seeks longer flexibility.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.